factor-beta (TGF-β) concentration, and that expression of VEGF-C and markers of lymphatics was higher in ultrafiltration failure-peritoneum. 5 In cultured mesothelial cells and macrophages, TGF-β-induced VEGF-C expression was blocked by a TGF-β type I receptor (TGFβRI) inhibitor. 5 Furthermore, VEGF-C expression and lymphangiogenesis were suppressed by the TGFβRI inhibitor or by the cyclooxygenase-2 (COX-2) inhibitor, celecoxib, in chlorhexidine gluconate-induced peritoneal injury models. 5 Thus, we proposed that lymphangiogenesis in the peritoneal membrane, similar to renal fibrosis is linked with the fibrotic process via the TGF-β-VEGF-C pathway. [6] [7] [8] The lymphatic absorption rate, which is measured by the rate at which intraperitoneally administered radioactive serum albumin or the macromolecule dextran 70 disappears, is significantly higher in patients with ultrafiltration failure, and lymphatic absorption is considered to be one of the causes of the decrease in net ultrafiltration. [9] [10] [11] [12] However, the results from these clinical approaches have been controversial, 13, 14 and there are no other methods available to assess lymphatic function.
In the present study, we investigated whether VEGF receptor-3 (VEGFR-3), the receptor for VEGF-C and -D, might be a new target to increase net ultrafiltration by suppression of lymphangiogenesis using an adenovirusexpressing soluble VEGFR-3 (Adeno-sVEGFR-3) fused with human IgG (Supplementary Figure 1) in models of murine peritoneal injury induced by methylglyoxal (MGO). [15] [16] [17] MGO is a precursor of advanced glycation end products, which accumulate in dialysis patients. 18 In addition, we proposed a new method for the peritoneal equilibration test by using a 7.5% icodextrin peritoneal dialysis solution (7.5% icodextrin peritoneal equilibration test) to assess lymphatic absorption (Supplementary Figure 1) . Finally, we studied the expression of VEGF-D in lymphangiogenesis in human samples.
MATERIALS AND METHODS MGO-Induced Peritoneal Injury Model
All animal studies were carried out in accordance with the Animal Experimentation Guidelines of Nagoya University Graduate School of Medicine (Nagoya, Japan). Ten-week-old male C57BL/6J mice (Japan SLC, Hamamatsu, Japan) initially weighing 24-29 g were used throughout the study. The animals were maintained under conventional laboratory conditions and had free access to food and water. The mice received an intraperitoneal injection of 100 ml/kg body weight of peritoneal dialysis fluid (Dianeal-N PD-4-2.5, 2.27% glucose, Baxter, Tokyo, Japan) containing 20 mmol/l MGO (MP Biomedicals LLC, Illkirch, France) for 3 weeks, 5 consecutive days per week as described previously 17 (Experiment 1, Supplementary Figure 2a) . Control mice received the same dosage of peritoneal dialysis fluid without MGO. This peritoneal dialysis fluid was prepared by purification through a 0.2-μm pore-size filter and by adjustment to pH 5.0 immediately before injection every day. The mice were killed on day 22, and parietal peritoneal and diaphragmatic samples were procured. The harvested samples were used for immunohistochemical analysis of lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), VEGFR-3, CD31, type III collagen, CD68, and VEGF-D, and for analysis of the mRNA expression of VEGF-D, VEGFR-3, LYVE-1, and CD31.
MGO Model Mice and Studies of Lymphangiogenesis Inhibition using an Adenovirus Vector
The experimental design and protocols are as follows (Supplementary Figure 2) : (a) Experiment 1: development of a MGO-induced peritoneal injury model in mice. The mice received peritoneal dialysis fluid (100 ml/kg) with MGO (20 mM) intraperitoneally from day 1 until day 22 (Supplementary Figure 2a) . (b) Experiment 2: inhibition studies using an adenovirusexpressing sVEGFR-3 and a control adenovirusexpressing Lac Z in a MGO-induced peritoneal injury model. Recombinant Adeno-sVEGFR-3 or β-galactosidase (Adeno-LacZ) were kindly provided by K Alitalo (the University of Helsinki, Helsinki, Finland) and were amplified and purified for use as described previously. [19] [20] [21] On day 0, prior to establishment of MGO-induced peritoneal injury as in a, the mice were first administered 1.0 × 10 9 p.f.u. of one of the adenoviral vectors intravenously through the tail vein. On day 22, the mice were assessed using a conventional peritoneal equilibration test with a 4.25% glucose-based peritoneal dialysis fluid and a peritoneal equilibration test with 7.5% icodextrin (Adeno-LacZ Day 22 group and AdenosVEGFR-3 Day 22 groups; Supplementary Figure 2b) . (c) Experiment 3: development of a MGO-induced peritoneal injury model with peritoneal rest from day 22 to day 50. The mice were treated as in a until day 22. From day 22 until their sacrifice on day 50 no dialysate was infused into the peritoneal cavity (peritoneal rest) (Supplementary Figure 2c) . (d) Experiment 4: inhibition studies using adenovirusexpressing sVEGFR-3 and control adenovirus-expressing Lac Z in a MGO model as in b except that the mice further underwent peritoneal lavage using a 1.5% peritoneal dialysis fluid from day 22 to day 50. For this treatment, the mice received an intraperitoneal injection of 100 ml/kg body weight of a low concentration peritoneal dialysis fluid (Dianeal-N PD-4 1.5, 1.36% glucose) for 20 days, 5 consecutive days per week. This procedure is similar to a previously reported method. 22 In these mice, peritoneal functions were assessed on day 50 using a conventional peritoneal equilibration test with a 4.25% glucose-based peritoneal dialysis fluid and a peritoneal equilibration test with a 7.5% icodextrin peritoneal dialysis fluid (AdenoLacZ Day 50 group and Adeno-sVEGFR-3 Day 50 group; Supplementary Figure 2d ).
Tissue and blood samples were also obtained from the mice for further analysis.
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Histology and Immunohistochemistry
Routine histological and immunohistological analyses of animal and human tissues were performed and assessed as we described previously. [5] [6] [7] 23, 24 The antibodies used are listed in Supplementary Table 1 . Mast cells were evaluated using sections stained with 0.2% toluidine blue.
RNA Preparation from Peritoneal and Diaphragm
Tissues, and PCR Analysis Animal peritoneal and diaphragm tissues were immersed in RNAlater (Ambion, Austin, TX, USA) for 41 day. RNA preparation and the synthesis of first-strand cDNA were performed as described previously. [5] [6] [7] 23, 24 Total RNA (1 μg) was then reverse transcribed. Quantitative real-time PCR (qPCR) analysis was performed with an Applied Biosystems (South San Francisco, CA, USA) Prism 7500HT sequence detection system using TaqMan gene expression assays as described previously. 24 The TaqMan Gene Expression Assays (Applied Biosystems) used are described in Supplementary Table 2. 18S ribosomal RNA was used as an endogenous control. 5, 7, 23, 24 Assessment of Lymphatic Absorption To assess absorption via the lymphatic vessels, animals that received 2000 μl of 7.5% icodextrin peritoneal dialysis solution into the peritoneal cavity were killed at 4 h after infusion. An accurate drained volume was measured.
Enzyme-Linked Immunosorbent Assays (ELISAs)
The concentration of sVEGFR-3-Ig fusion protein in the serum was determined using an ELISA kit for human IgG1 (Cayman Chemical Company, Ann Arbor, MI, USA) as described previously. 25 Levels of VEGF-D protein and prostaglandin E2 (PGE2) in the peritoneal dialysis effluent were measured using the ELISA kits for human VEGF-D (R&D Systems, Minneapolis, MN, USA) and PGE2 (Cayman Chemical Company), respectively, according to the manufacturers' instructions. The samples were frozen at the time of collection and were stored at − 80°C. The samples were not subjected to freeze-thaw cycles.
Human Patient Studies
All of the studies were approved by the Ethics Committee for Human Research of the Faculty of Medicine, Nagoya University (Approval #298 and #299). All patients provided informed consent prior to participation in this study.
VEGF-D Concentration in the Peritoneal Effluent of Peritoneal Dialysis Patients
The VEGF-D concentrations in dialysates were measured in overnight-dwelled (8.95 ± 1.63 h) samples collected from 83 peritoneal dialysis patients (27 women and 56 men) who were treated between July 2005 and April 2008 in the Department of Nephrology and Renal Replacement Therapy of Nagoya University Hospital (Nagoya, Japan) and at affiliated hospitals. 5 This is the same cohort in which VEGF-C was measured in recent studies. 5 The mean age of all patients was 55.9 ± 13.5 (range, 28 to 89) years, and the mean duration of peritoneal dialysis treatment was 31.9 ± 32.0 (range, 1 to 132) months. 5 Diabetic nephropathy was the cause of end-stage renal disease in 27 peritoneal dialysis patients (32.5%). All patients were free from peritonitis for at least 1 month prior to the study, and patients with other diseases, such as liver or lung diseases and malignancy, were excluded. Patients undergoing combination therapy (hemodialysis+peritoneal dialysis) were not included in this study. Peritoneal membrane transport was assessed based on the dialysate to plasma ratio of creatinine, and the average value was 0.67 ± 0.14 (range, 0.28 to 0.96). 5 A fast peritoneal equilibration test was performed using a 2.27% glucose-based dialysis solution (Dianeal-N PD-4) as described by Twardowski et al (Supplementary Information 1) . 26 The correlation between VEGF-D concentration in the peritoneal dialysis effluent and the dialysate to plasma ratio of creatinine was analyzed. In addition, we measured the VEGF-D concentration in peritoneal effluent samples at 4 h of the peritoneal equilibration test. These samples were collected from 40 peritoneal dialysis patients (13 women and 27 men) treated between November 2008 and June 2009 at the Handa Municipal Hospital and the Nagoya University Hospital. The mean age of all patients was 52.9 ± 10.9 (range, 30 to 70) years, and the mean duration of peritoneal dialysis treatment was 26.1 ± 24.6 (range, 1 to 103) months. 5, 23 VEGF-D mRNA Expression in the Human Peritoneum Fifty-four peritoneal tissue samples were obtained from 29 peritoneal dialysis patients and 25 pre-dialysis chronic renal failure patients at the time of peritoneal dialysis catheter insertion. Among the 29 peritoneal dialysis patients, 7 were regarded as having impaired ultrafiltration capacity, which was defined as described previously. 5, 23, 27 Twenty-two patients (incident) had their catheters removed because of transplantation, severe exit site infection, mental disorders, or difficulty in performing the bag exchanges (Table 1) .
VEGF-D mRNA Expression in the Cultured Mesothelial Cells
Reverse Transcription-PCR (RT-PCR) was performed using the HotStarTaq PCR kit (Qiagen, Tokyo, Japan) 7, 28 to examine whether VEGF-D mRNA was expressed in three kinds of mesothelial cells: the human mesothelial cell line Met5A, 5, 23 mesothelial cells from the peritoneal dialysis effluent of the patients on peritoneal dialysis, 5, 23 and mesothelial cells derived from the omentum. 29, 30 The primers according to the reported sequences of human VEGF-D and GAPDH were 5ʹ-GTATGGACTCTCGCTCAGCAT-3ʹ (sense) and 5ʹ-AGGCTCTCTTCATTGCAACAG-3ʹ (antisense, PCR products 225 bp); 31 and 5ʹ-ATCATCCCTGCCTCTACTGG-3ʹ (sense) and 5ʹ-CCCTCCGACGCCTGCTTCAC-3ʹ (antisense, PCR products 188 bp), 28 respectively.
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Statistical Analyses
The 
RESULTS
Lymphangiogenesis Developed in a MGO-Induced Peritoneal Injury Model
Twenty-two days after administration of MGO (Experiment 1, Supplementary Figure 2a ) LYVE-1-and podoplaninpositive lymphatic vessels were increased and dilated in the diaphragm of MGO model mice compared with controls ( Figure 1a ,Supplementary Figure 3) ; however, lymphangiogenesis was not pronounced or significant in the parietal peritoneum wall ( Figure 1a ). In contrast, as shown in 
VEGFR-
To investigate whether these occurrences of lymphangiogenesis were enhanced via VEGFR-3 activation, we performed inhibition studies using Adeno-sVEGFR-3, which traps both its VEGF-C and VEGF-D ligands. Serum sVEGFR-3 was detected on days 22 and 50 after its administration via tail vein injections, and its concentration was significantly higher on both days in mice injected with Adeno-sVEGFR-3 than in mice treated with Adeno-LacZ (Supplementary Figure 7) . These results are consistent with previous reports. 19 Figure 9a) . qPCR analysis indicated that, on day 22, LYVE-1 and VEGFR-3 mRNA were significantly suppressed by Adeno-sVEGFR-3 compared with Adeno-LacZ; however, neither VEGF-C nor VEGF-D mRNA or protein expression was significantly changed between the two groups ( Figure 5 , Supplementary Figure 9b and c). VEGF-C and -D proteins were undetectable in the serum of both groups. The extent of neoangiogenesis and fibrosis as assessed by analysis of CD31 and TGF-β1 mRNA levels was similar between the two groups (Figure 5e and f). These findings suggest that Adeno-sVEGFR-3 treatment specifically blocked the VEGFR-3 signaling pathway.
Analysis of Lymphatic Absorption on Day 22
To assess suppression of lymphangiogenesis by AdenosVEGFR-3, we performed a peritoneal equilibration test on day 22 using a 7.5% icodextrin peritoneal dialysis solution (Extraneal, Baxter), which is mainly absorbed via the lymphatic system. 33 In this peritoneal equilibration test (7.5% icodextrin peritoneal equilibration test), effluent volume was recovered in mice in which lymphangiogenesis was suppressed by administration of Adeno-sVEGFR-3 ( Figure 6a ), although angiogenesis as assessed by CD31 
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analyses was similar between the Adeno-LacZ and AdenosVEGFR-3 groups (Figures 4b and 5e ). Subsequently, we performed a conventional peritoneal equilibration test using a 4.25% glucose-based peritoneal dialysis fluid (4.25%G-peritoneal equilibration test, Dianeal) to assess peritoneal membrane transport. There was no difference in transport rates between the Adeno-LacZ and Adeno-sVEGFR-3 groups (Supplementary Figure 10a and b) . On day 22, peritoneal inflammation associated with strong CD68-positive macrophage infiltration was shown (Figure 4d ). It was thus considered that assessment of the peritoneal membrane function in mice was unsuitable under these conditions, as it is in human peritoneal dialysis patients with peritonitis. 34 We therefore re-assessed the peritoneal equilibration test after resolution of inflammatory changes in the peritoneal membranes. For this purpose, after development of lymphangiogenesis in MGO models on day 22, the mice were observed for 4 weeks to watch for reduction in peritoneal inflammation (Experiment 3, Supplementary Figure 2c ). However, we had difficulty in performing the peritoneal equilibration test on day 50 because there were several adhesions in the peritoneal cavity due to inflammation in the peritoneum (Supplementary Figure 11a) . Therefore, to prevent adhesions and to reduce the peritoneal inflammation, we administered a low concentration (1.5%) of a glucose-based peritoneal dialysis fluid into the peritoneal cavity 5 days per week from day 22 to day 50 (Experiment 4, Supplementary Figure 2d) .
Analysis of Pathology and Function in the Peritoneal
Membrane on Day 50 After Administration of a 1.5% Glucose-Based Solution for 4 Weeks We found that peritoneal inflammation was successfully reduced by administration of the 1.5% glucose-based peritoneal dialysis fluid into the peritoneal cavity for 4 weeks, which enabled performance of a peritoneal equilibration test on day 50 (Supplementary Figure 11b) . Leakage of PGE2 into the effluent, COX-2 mRNA expression, CD68-positive macrophages, and mast cell infiltration in the diaphragm were reduced on day 50 compared with day 22 in the AdenoLacZ and Adeno-sVEGFR-3 groups (Figures 4d and 7) . On day 50, the lymphatic vessels that were suppressed on day 22 continued to be suppressed in the Adeno-sVEGFR-3 group, and both the lymphangiogenesis and neoangiogenesis conditions were preserved from day 22 to day 50 (Figure 4a and b) . 
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Apparently, the progression of fibrosis as assessed by type III collagen expression was more advanced on day 50 compared with that on day 22; however, the extent of fibrosis was not different between the Adeno-sVEGFR-3 and Adeno-LacZ groups (Figure 4c) . On day 50, we found a significant difference in fluid removal between the two groups in the 7.5% icodextrin peritoneal equilibration test (Figure 6a ). This result indicates that the 7.5% icodextrin peritoneal equilibration test can assess fluid absorption via lymphatic vessels. In the 4.25%G-peritoneal equilibration test, we found a significant difference on day 22 between the control mice and the MGO model mice in the ratio of dialysate glucose at 2 h dwell time to dialysate glucose at 0 h dwell time; however, there was no difference on day 50, suggesting that the low levels on day 22 may be due to vascular permeability with strong inflammation (Figure 7 and Supplementary Figure  10a ). In addition, there was no difference in the ratio of dialysate glucose at 2 h dwell time to dialysate glucose at 0 h or in the dialysate to plasma ratio of creatinine between the groups (Supplementary Figure 10a and Figure 12) . Amylase concentration in the effluent was not different between the two groups on day 22 or day 50 (Figure 6b ).
VEGF-D Concentration in Human Peritoneal
In human peritoneal dialysis patients, VEGF-D concentration was correlated with the dialysate to plasma ratio of creatinine in the peritoneal dialysis effluent of samples dwelled for 4 h (R = 0.622, Po0.001, Figure 8a) . We further measured VEGF-D concentration in the overnight-dwelled peritoneal dialysis effluent of 83 patients; we found a positive correlation between the dialysate VEGF-D concentration and the dialysate to plasma ratio of creatinine (R = 0.516, Po0.001, Figure 8b ). We assessed the VEGF-D mRNA expression in the peritoneal membrane of human biopsy samples (Table 1) . VEGF-D mRNA was significantly higher in the peritoneum of ultrafiltration failure patients than in the peritoneal membrane from patients on peritoneal dialysis without ultrafiltration failure or from patients with pre-dialysis uremia (Figure 8c) . In ultrafiltration failure, VEGFR-3 and LYVE-1 mRNA expression was elevated compared with the other patients (Figure 8d and Supplementary Figure 13) . VEGF-D was mainly detected in CD68-positive macrophages of peritoneal biopsy samples of ultrafiltration failure patients (Figure 8e) , which was similar to observations in the animal models (Figure 3b and c) .
DISCUSSION
In the majority of organs, one of the main functions of lymphatic vessels is to return fluid and macromolecules to the vascular system. 35, 36 In peritoneal dialysis, the net ultrafiltration volume at the end of an exchange equals the cumulative net transcapillary water transport minus the lymphatic absorption during the exchange; 37 therefore, control of lymphatic absorption is important to obtain higher drained volume. In a previous study using human materials and rat chlorhexidine gluconate models, we showed that lymphangiogenesis developed in the peritoneal cavity. 5 In the present study, we demonstrated that lymphangiogenesis developed in rodent MGO models and found that lymphatic vessels grow in association with inflammatory changes, especially in the diaphragm. These findings and our previous studies 5 indicate that lymphangiogenesis is a common feature in the peritoneal cavity, together with inflammation and fibrosis, and that lymphangiogenesis is more predominant in the diaphragm compared with that in the parietal peritoneal membrane. Interestingly, in the MGO model animals on day 22, VEGF-D was significantly increased in the diaphragms of mice (Po0.01, Figure 2 , Po0.05, Supplementary Figure 5) and rats (Po0.05, Supplementary Figure 6) ; however, VEGF-C was not significantly upregulated ( Figure 2 , Supplementary  Figures 5 and 6 ). This situation was different from that of the chlorhexidine gluconate models. 5 In the chlorhexidine gluconate models of our previous studies, lymphangiogenesis was suppressed by COX-2 inhibitors; however, these drugs are not suitable for peritoneal dialysis patients in terms of preservation of residual renal function and are not suitable as specific inhibitors of lymphangiogenesis. 5 VEGFR-3, a receptor for both VEGF-C and -D, is expressed by lymphatic endothelial cells and is upregulated in both MGO (Figure 2,  Supplementary Figure 6 ) and chlorhexidine gluconate models; 5 we therefore considered that VEGFR-3 is suitable as a target molecule to suppress lymphangiogenesis in the Figures 1 and 14) . In our previous studies, 5 we used immunofluorescence microscopy to detect the passage of fluorescein isothiocyanate (FITC)-dextran (molecular weight 2 000 000), which can only be absorbed through the lymphatic vessels in the diaphragm, and detected high FITC-dextran levels in the serum of the chlorhexidine gluconate models. 5 However, these methods are not appropriate for peritoneal dialysis patients. Therefore, we tried to develop practical methods using a 7.5% icodextrin peritoneal dialysis solution, which reflects lymphatic functions. Icodextrin is a glucose polymer osmotic agent that is used to promote sustained ultrafiltration during long peritoneal dialysis dwells. 33, 38 The disappearance of icodextrin from the peritoneal cavity was reported to be consistent with a constant rate of fluid transport from the peritoneal cavity, mainly via the lymphatics. 33 In our experiments, the drained volume of the 7.5% icodextrin peritoneal equilibration test identified the upregulation and suppression of lymphangiogenesis, even in the presence of inflammation on day 22 (Figure 6a ). It has been reported that protein and solutions pass into the lymphatic capillaries without sieving 14 because they have anatomically discontinuous basal lamina and have gaps between the lymphatic endothelial cells. 6, 35 This finding is in agreement with there being no difference in glucose and creatinine transport rates between the conditions of suppression and lack of suppression of lymphangiogenesis (Supplementary Figure 10) . In the 4.25% G-peritoneal equilibration test, the drained volume tended to be increased in the Adeno-sVEGFR-3 groups, but the difference versus the volume in the Adeno-LacZ group was not statistically significant (Supplementary Figure 10c) . This result suggests that the 4.25% G-peritoneal equilibration test may be unsuitable for identifying the different states of lymphatic absorption. In the use of icodextrin solution in rodents, the reduction in recovery volume was shown to result from degradation of icodextrin by 10-to 25-fold higher levels of amylase compared with humans. 39, 40 The low drained volume in the 7.5% icodextrin peritoneal equilibration test on day 22 was probably therefore due to high amylase concentrations ( Figure 6 ). We did not find any differences in amylase concentrations in peritoneal dialysis effluent between the Adeno-sVEGFR-3 and Adeno-LacZ groups (Figure 6b ). We performed the 7.5% icodextrin peritoneal equilibration test for a short duration of 4 h, under which condition the removal of fluid from the circulation by the oncotic pressure of icodextrin solution may not be strongly affected. However, VEGFR-3 is a target to improve ultrafiltration T Terabayashi et al to determine whether these methods might be available for peritoneal dialysis patients, future detailed studies, including studies of optimal conditions, are necessary.
We successfully evaluated peritoneal membrane function after peritoneal rest with lavage for reduction of inflammation. These results suggest that peritoneal lavage before removal of the peritoneal dialysis catheter after prolonged peritoneal dialysis treatment 41 may be useful to prevent adhesions that could lead to encapsulating peritoneal sclerosis. 
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In MGO model animals, VEGF-D that is expressed mainly by macrophages is a key growth factor for lymphangiogenesis in the peritoneal cavity, especially in the diaphragm (Figures 2b and 3b, c and Supplementary Figure 6) . In cultured macrophages and fibroblasts, VEGF-D has been reported to be increased by PGE2, 42 which was elevated in the effluent of MGO model mice (Figure 7) , and by inflammatory cytokines. 43 In contrast to VEGF-C, VEGF-D was downregulated by TGF-β. 44 We have reported that mesothelial cells strongly express VEGF-C; 5 however, VEGF-D was not expressed by mesothelial cells in the MGO model mice or in cultured human mesothelial cells (Figure 3d and e) . These instances of expression and regulation of VEGF-D are different from those of VEGF-C. We are the first to report that VEGF-D is increased in the human peritoneal membrane and in the peritoneal dialysis effluent with ultrafiltration failure (Figure 8 ). These data indicate that VEGF-D is involved in lymphangiogenesis in human peritoneal dialysis patients.
In summary, lymphatic absorption is a common feature associated with peritoneal inflammation and fibrosis, and VEGF-D is involved in the development of lymphangiogenesis. VEGFR-3 is a new target to increase net ultrafiltration by suppressing lymphatic absorption.
Supplementary Information accompanies the paper on the Laboratory Investigation website (http://www.laboratoryinvestigation.org)
